State of Alaska Department of Revenue Reduces Holdings in Amedisys, Inc. (NASDAQ:AMED)

State of Alaska Department of Revenue trimmed its stake in Amedisys, Inc. (NASDAQ:AMED) by 10.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,527 shares of the health services provider’s stock after selling 390 shares during the period. State of Alaska Department of Revenue’s holdings in Amedisys were worth $335,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of AMED. Neo Ivy Capital Management purchased a new position in shares of Amedisys in the 2nd quarter valued at $44,000. Covestor Ltd grew its position in Amedisys by 88.9% during the 1st quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after purchasing an additional 152 shares during the last quarter. Acadian Asset Management LLC purchased a new position in Amedisys during the 1st quarter worth $67,000. Lazard Asset Management LLC purchased a new position in Amedisys during the 1st quarter worth $68,000. Finally, FNY Investment Advisers LLC grew its position in Amedisys by 22,122.2% during the 3rd quarter. FNY Investment Advisers LLC now owns 2,000 shares of the health services provider’s stock worth $186,000 after purchasing an additional 1,991 shares during the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Stock Down 0.4 %

Shares of NASDAQ AMED opened at $91.90 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys, Inc. has a 52 week low of $73.10 and a 52 week high of $96.44. The firm has a 50-day moving average price of $93.05 and a 200 day moving average price of $93.49. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of -296.44, a price-to-earnings-growth ratio of 4.34 and a beta of 0.86.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, February 21st. The health services provider reported $0.94 EPS for the quarter, missing the consensus estimate of $1.04 by ($0.10). Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The company had revenue of $570.79 million during the quarter, compared to analyst estimates of $566.85 million. During the same quarter last year, the business earned $1.16 EPS. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. Equities research analysts anticipate that Amedisys, Inc. will post 4.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on AMED shares. StockNews.com started coverage on shares of Amedisys in a research report on Monday, April 8th. They set a “buy” rating on the stock. Royal Bank of Canada raised their price objective on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 25th. Finally, Raymond James restated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Seven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $97.50.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.